ImmuneOncia Therapeutics, Inc. (KOSDAQ:424870)
South Korea · Delayed Price · Currency is KRW 2,890.00
+85.00 (3.03%)
At close: Sep 4, 2026
ImmuneOncia Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | - | 111.21 | 654.54 | 110 | 7,733 | 35.95 |
Other Revenue | - | - | - | - | - | 0 |
| - | 111.21 | 654.54 | 110 | 7,733 | 35.95 | |
Revenue Growth | - | -83.01% | 495.04% | -98.58% | 21413.29% | 1337.90% |
Cost of Revenue | 14.38 | 12.95 | 11.12 | 17.09 | 17.85 | 7.8 |
Gross Profit | -14.38 | 98.26 | 643.42 | 92.91 | 7,716 | 28.15 |
Selling, General & Admin | 4,452 | 7,439 | 4,964 | 5,038 | 7,662 | 5,075 |
Research & Development | 24,953 | 19,821 | 7,386 | 6,034 | 14,243 | 6,012 |
Amortization of Goodwill & Intangibles | 577.94 | 575.73 | 574.44 | 565.53 | 567.15 | 567.03 |
Other Operating Expenses | 31.54 | 35.77 | 19.64 | 19.55 | 15.15 | 12.63 |
Operating Expenses | 30,171 | 28,103 | 13,242 | 11,890 | 22,789 | 11,924 |
Operating Income | -30,186 | -28,005 | -12,599 | -11,797 | -15,073 | -11,896 |
Interest Expense | -4.27 | -5.12 | -6.93 | -3.13 | - | - |
Interest & Investment Income | 1,031 | 706.03 | 690.31 | 769.15 | - | - |
Currency Exchange Gain (Loss) | -128.65 | -41.66 | -49.41 | 9.51 | 75.7 | 192.43 |
Other Non Operating Income (Expenses) | -18.13 | -17.66 | 6,278 | 19,886 | 11,507 | -48,783 |
EBT Excluding Unusual Items | -29,306 | -27,363 | -5,686 | 8,865 | -3,490 | -60,487 |
Gain (Loss) on Sale of Assets | - | - | -0.55 | -0.77 | -1.38 | -3.18 |
Pretax Income | -29,306 | -27,363 | -5,687 | 8,864 | -3,492 | -60,490 |
Net Income | -29,306 | -27,363 | -5,687 | 8,864 | -3,492 | -60,490 |
Net Income to Common | -29,306 | -27,363 | -5,687 | 8,864 | -3,492 | -60,490 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 76 | 70 | 56 | 52 | 52 | 46 |
Shares Outstanding (Diluted) | 76 | 70 | 56 | 52 | 52 | 46 |
Shares Change | 21.39% | 24.72% | 7.35% | 0.64% | 12.17% | 904.47% |
EPS (Basic) | -385.56 | -389.65 | -101.00 | 169.00 | -67.00 | -1302.00 |
EPS (Diluted) | -385.56 | -389.65 | -101.00 | 169.00 | -67.00 | -1302.00 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -26,676 | -23,105 | -14,757 | -8,766 | -15,337 | -2,078 |
Free Cash Flow Per Share | -350.96 | -329.02 | -262.08 | -167.13 | -294.29 | -44.72 |
Gross Margin | - | 88.36% | 98.30% | 84.47% | 99.77% | 78.31% |
Operating Margin | - | -25182.04% | -1924.80% | -10724.51% | -194.91% | -33093.66% |
Profit Margin | - | -24605.12% | -868.86% | 8058.20% | -45.15% | -168272.99% |
Free Cash Flow Margin | - | -20776.54% | -2254.59% | -7968.93% | -198.32% | -5779.96% |
EBITDA | -29,341 | -27,114 | -11,547 | -10,766 | -13,992 | -10,870 |
EBITDA Margin | - | - | - | - | -180.93% | - |
D&A For EBITDA | 845.07 | 890.41 | 1,051 | 1,031 | 1,081 | 1,026 |
EBIT | -30,186 | -28,005 | -12,599 | -11,797 | -15,073 | -11,896 |
EBIT Margin | - | - | - | - | -194.91% | - |
Advertising Expenses | - | 2.08 | 1 | 1 | - | - |